Buffalo, NY., February 12, 2025 Highlights: Ongoing clinical trial of SurVaxM in glioblastoma [SURVIVE] has successfully progressed following an interim analysis of trial data The clinical trial is designed to evaluate the safety,…
SurVaxM is the first drug product to be produced in UI Pharmaceuticals new facility
MimiVax Granted Fast Track Designation from FDA for SurVaxM for Newly Diagnosed Glioblastoma
SurVaxM appeared to be safe and well-tolerated in pts with nGBM. SurVaxM was effective at stimulating survivin-specific immune responses and the primary endpoint was met.
First center to treat newly diagnosed glioblastoma patients as part of late-stage trial with SurVaxM BUFFALO, N.Y. — Roswell Park Comprehensive Cancer Center is the first center to treat patients…